Two Sigma Advisers
TOVX icon

Two Sigma Advisers’s Theriva Biologics TOVX Stock Holding History

Two Sigma Advisers’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-27,284
Closed -$11.1K – 2626
2025
Q3 		$11.1K Buy
+27,284
New +$11.8K ﹤0.01% 2310
2023
Q1 		– Sell
-480
Closed -$5.45K – 2750
2022
Q4 		$5.45K Sell
480
-16
-3% -$291 ﹤0.01% 2474
2022
Q3 		$12K Sell
496
-45
-8% -$1.73K ﹤0.01% 2472
2022
Q2 		$29K Sell
541
-20
-4% -$1.15K ﹤0.01% 2525
2022
Q1 		$40K Sell
561
-97
-15% -$6.61K ﹤0.01% 2613
2021
Q4 		$45K Buy
658
+145
+28% +$13.7K ﹤0.01% 2481
2021
Q3 		$59K Buy
513
+378
+280% +$47K ﹤0.01% 2359
2021
Q2 		$20K Buy
+135
New +$19.3K ﹤0.01% 2411

Other funds holding TOVX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return

Two Sigma Advisers's TOVX Position: Q4 2025 in Review

Two Sigma Advisers sold out of Theriva Biologics (TOVX) in Q4 2025, closing a stake of 27,284 shares — an estimated $11.1K sold.

Two Sigma Advisers first reported a position in TOVX in Q2 2021 and held it in 8 quarters. The position peaked at $59K in Q3 2021. 21 funds tracked by Wall St. Rank hold TOVX as of Q4 2025.

  • Two Sigma Advisers reported no remaining Theriva Biologics position as of Q4 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 27,284 Theriva Biologics shares in Q4 2025, an estimated $11.1K.
  • Two Sigma Advisers first reported a position in Theriva Biologics in Q2 2021 and held it in 8 quarters.
  • Two Sigma Advisers's Theriva Biologics position peaked at $59K in Q3 2021.
  • 21 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2025.

Based on Two Sigma Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.